DCGO

EX-99.1

4 ex-991xq226xer.htm

EX-99.1

Document

Exhibit 99.1

DocGo Announces Second Quarter 2026 Results

Company Signs Definitive Agreement to Acquire Virtual Care Provider Hicuity Health,

Perceptive Advisors Commits to New Term Loan Funding

Management to Host Conference Call and Webcast Today at 5:00 PM Eastern Time

NEW YORK, NY, August 17th, 2026 – DocGo Inc. (Nasdaq: DCGO) (“DocGo” or the “Company”), a leading provider of technology-enabled mobile health and medical transportation services, today announced financial and operating results for the second quarter ended June 30, 2026.

Second Quarter 2026 Financial Highlights

•Total revenue for the second quarter of 2026 was $73.4 million, compared to $80.4 million in the second quarter of 2025. This decline was entirely due to the wind-down of migrant-related programs, which generated zero revenue in the second quarter of 2026 and $18.8 million in the second quarter of 2025. Excluding revenue from migrant-related programs, total revenue increased 19% year over year.

•GAAP gross margin (which includes depreciation and amortization expenses) for the second quarter of 2026 was 26.9%, compared to 26.7% in the second quarter of 2025.

•Adjusted gross margin1 for the second quarter of 2026 was 30.5%, compared to 31.6% in the second quarter of 2025.

•Net income for the second quarter of 2026 was ($18.0) million, compared to net income of ($13.3) million in the second quarter of 2025.

•Adjusted EBITDA1 was ($6.3) million for the second quarter of 2026, compared to adjusted EBITDA of ($6.1) million for the second quarter of 2025.

•Medical Transportation Services revenue in the second quarter of 2026 was $52.0 million, compared to $49.6 million for the second quarter of 2025. Mobile Health Services revenue for the second quarter of 2026 was $21.4 million, compared to $30.8 million for the second quarter of 2025. This decline was entirely due to the wind-down of migrant-related programs. Excluding revenue from migrant-related programs, Mobile Health Services revenue increased 78% to $21.4 million in the second quarter of 2026 from $12.0 million in the second quarter of 2025, driven by organic growth and the inclusion of revenue from SteadyMD.

•As of June 30, 2026, the Company held total cash and cash equivalents, including restricted cash and investments, of approximately $48.1 million, compared to $59.9 million as of March 31, 2026. Unrestricted cash and cash equivalents was $25.2 million as of June 30, 2026, compared to unrestricted cash of $35.7 million as of March 31, 2026.

Select Corporate Highlights for the Second Quarter of 2026 and Recent Weeks

•Company achieved record volumes across all major business lines, with US medical transportation increasing 15%, healthcare in the home increasing 26%, mobile phlebotomy

increasing 20%, cardiac and remote patient monitoring increasing 13%, and virtual care & lab orders increasing 58% when comparing the second quarter of 2026 to the second quarter of 2025.

•Company surpassed 1.7 million patients assigned by the Company’s payer and provider partners to engage for care gap closure services since inception, up 100,000 patients from last quarter.

•Signed a new contract with one of the largest national health plans to offer care gap closure services to their members in Pennsylvania.

•Launched mobile phlebotomy services in Southern Florida, expanding relationship with a major national clinical laboratory and positioning the company for mobile phlebotomy growth in the Southeast.

Hicuity Health Acquisition & Perceptive Financing

•Company has entered into a definitive agreement to acquire 100% of virtual care provider, Hicuity Health.

•Hicuity delivers high acuity virtual clinical care – including Tele-ICU, Virtual Nursing, and Telemetry Monitoring services – for health systems, hospitals and post-acute facilities.

•On a trailing 12-month basis, Hicuity generated approximately $65 million in revenue and $4.5 million of adjusted EBITDA.

•DocGo is acquiring Hicuity in exchange for the assumption of the company’s existing indebtedness held by Perceptive Advisors, which is estimated to be approximately $52 million at closing, which will now mature in December 2029.

•Hicuity’s preferred shareholder will receive equity representing approximately 2.0% of DocGo’s currently outstanding common stock and may receive an additional 3.5% of currently outstanding common stock if DocGo achieves a market capitalization of $250 million within three years of closing.

•Perceptive Advisors has committed to provide up to an additional $50 million of debt financing to DocGo, expected to be made available in multiple tranches, the first $12.5 million of which will be funded upon Hicuity and DocGo entering into a services agreement pursuant to which DocGo will provide management related services to Hicuity during the pre-closing period.

Financial Guidance

•Full-year 2026 revenue range is narrowed to $305-$310 million, compared

EX-99.1

2 ex-991xq126xer.htm

EX-99.1

Document

Exhibit 99.1

DocGo Announces First Quarter 2026 Results

Company Increases 2026 Revenue Guidance Based on Strong Demand for Virtual Care Services

Management to Host Conference Call and Webcast Today at 5:00 PM Eastern Time

NEW YORK, NY, May 11th, 2026 – DocGo Inc. (Nasdaq: DCGO) (“DocGo” or the “Company”), a leading provider of technology-enabled mobile health and medical transportation services, today announced financial and operating results for the first quarter ended March 31, 2026.

First Quarter 2026 Financial Highlights

•Total revenue for the first quarter of 2026 was $75.6 million, compared to $96.0 million in the first quarter of 2025. This decline was entirely due to the wind-down of migrant-related programs, which generated zero revenue in the first quarter of 2026 and $35.0 million in the first quarter of 2025. Excluding revenue from migrant-related programs, revenue increased 19.3% to $75.6 million in the first quarter of 2026 from $61.0 million in the first quarter of 2025.

•GAAP gross margin (which includes depreciation and amortization expenses) for the first quarter of 2026 was 28.1%, compared to 28.2% in the first quarter of 2025.

•Adjusted gross margin1 for the first quarter of 2026 was 31.6%, compared to 32.1% in the first quarter of 2025.

•Net income for the first quarter of 2026 was ($16.7) million, compared to net income of ($11.1) million in the first quarter of 2025.

•Adjusted EBITDA1 was ($10.2) million for the first quarter of 2026, compared to adjusted EBITDA of ($3.9) million for the first quarter of 2025.

•Medical Transportation Services revenue in the first quarter of 2026 was $51.9 million, compared to $50.8 million for the first quarter of 2025.

•Mobile Health Services revenue for the first quarter of 2026 was $23.6 million, compared to $45.2 million for the first quarter of 2025. This decline was entirely due to the wind-down of migrant-related programs. Excluding revenue from migrant-related programs, Mobile Health Services revenue increased 131% to $23.6 million in the first quarter of 2026 from $10.2 million in the first quarter of 2025, driven by organic growth and the inclusion of revenue from SteadyMD.

•As of March 31, 2026, the Company held total cash and cash equivalents, including restricted cash and investments, of approximately $59.9 million, compared to $68.3 million as of December 31, 2025.

Select Corporate Highlights for the First Quarter of 2026 and Recent Weeks

•Combined revenues from the Company’s “healthcare at any address” business – which includes our care gap closure, transitions of care, remote patient monitoring, mobile phlebotomy and virtual care services – increased on a sequential basis from $12.8 million in the fourth quarter of 2025 to approximately $17.4 million in the first quarter of 2026, an increase of 36%.

•Company achieved record volumes across all major business lines, with US medical transportation increasing 17%, healthcare in the home increasing 46%, mobile phlebotomy increasing 8%, cardiac & remote patient monitoring increasing 13%, and virtual care & lab orders increasing 37% when comparing the first quarter of 2026 to the first quarter of 2025.

•SteadyMD entered into a new contract with a leading online pharmacy to provide virtual care services for weight loss prescriptions and a broad scope of general clinical services.

•Company’s Q1 health plan partnership client satisfaction survey found that 93% of survey participants were likely or very likely to recommend DocGo’s services, and a majority of survey participants said they plan on expanding services with DocGo in 2026.

•Company surpassed 1.6 million patients assigned by the Company’s payer and provider partners to engage for care gap closure services, up from 1.45 million last quarter.

•Company was one of 150 healthcare providers selected to participate in CMS’s ACCESS Model program, which is aimed at improving chronic disease management through technology-supported care.

•Company received two prestigious industry awards subsequent to quarter end – DocGo was recognized as one of the 2026 World's Most Ethical Companies® by Ethisphere, and was also awarded “Best Overall Healthcare Cybersecurity Company” in the 10th annual MedTech Breakthrough Awards.

Financial Guidance

•Full-year 2026 revenue is expected to be $300-$315 million, an increase from the Company’s prior guidance of $290-$310 million, and initial guidance of $280-$300 million.

•Full-year 2026 adjusted EBITDA2 is expected to be ($5-$10) million, unchanged from the Company’s prior guidance.

Lee Bienstock, Chief Executive Officer of DocGo, commented, “We continued to experience strong volumes across all key business verticals, and especially in our virtual care provider, SteadyMD. We now expect in excess of 50% top-line growth this year at SteadyMD compared to 2025, and even greater growth in our mobile phlebotomy business. As a result of this streng

EX-99.1

2 ex-991xfy2025xer.htm

EX-99.1

Document

Exhibit 99.1

DocGo Announces Fourth Quarter and Full Year 2025 Results

Company Raises 2026 Revenue and Adjusted EBITDA Guidance due to Customer Expansions, Improved EMS Hiring Rates and Efficiency Initiatives

Company Has Initiated a Formal Process to Explore Strategic Alternatives to Maximize Shareholder Value

Management to Host Conference Call and Webcast Today at 5:00 PM Eastern Time

NEW YORK, NY, March 16th, 2026 – DocGo Inc. (Nasdaq: DCGO) (“DocGo” or the “Company”), a leading provider of technology-enabled mobile health and medical transportation services, today announced financial and operating results for the fourth quarter and full year ended December 31, 2025.

Fourth Quarter 2025 Financial Highlights

•Total revenue for the fourth quarter of 2025 was $74.9 million, compared to $120.8 million in the fourth quarter of 2024. This decline was entirely due to the wind-down of migrant-related programs, which generated $7.4 million of revenue in the fourth quarter of 2025 and $60.2 million in the fourth quarter of 2024. Excluding revenue from migrant-related programs, revenue increased 11% to $67.5 million in the fourth quarter of 2025 from $60.6 million in the fourth quarter of 2024.

•GAAP gross margin (which includes depreciation and amortization expenses) for the fourth quarter of 2025 was 27.2%, compared to 30.8% in the fourth quarter of 2024.

•Adjusted gross margin1 for the fourth quarter of 2025 was 32.5%, compared to 33.5% in the fourth quarter of 2024.

•Net loss for the fourth quarter of 2025 was $142.3 million, compared to a net loss of $7.6 million in the fourth quarter of 2024. Included in this quarter’s loss were several non-cash items totaling $78 million, which include impairments of $23 million in intangible assets, $50 million in goodwill and $5 million in an equity investment.

•Adjusted EBITDA1 loss was $11.3 million for the fourth quarter of 2025, compared to adjusted EBITDA of $1.1 million for the fourth quarter of 2024.

•Medical Transportation Services revenue in the fourth quarter of 2025 was $50.2 million, compared to $49.1 million for the fourth quarter of 2024.

•Mobile Health Services revenue for the fourth quarter of 2025 was $24.8 million, compared to $71.8 million for the fourth quarter of 2024. This decline was entirely due to the wind-down of migrant-related programs. Excluding revenue from migrant-related programs, Mobile Health Services revenue increased 47% from the fourth quarter of 2024, aided by the inclusion of revenue from SteadyMD, which was acquired on October 20, 2025.

•As of December 31, 2025, the Company held total cash and cash equivalents, including restricted cash and investments, of approximately $68.3 million, compared to $95.2 million as of September 30, 2025. This period included $12.5 million in cash for the acquisition of SteadyMD and additional transaction-related cash payments of approximately $1.5 million.

Full Year 2025 Financial Highlights

•Total revenue for 2025 was $322.2 million, compared to $616.6 million in 2024. This decline was entirely due to the wind-down of migrant-related programs, which generated $69.6 million in 2025 and $373.5 million in 2024.

•GAAP gross margin (which includes depreciation and amortization expenses) for 2025 was 25.8%, compared to 32.1% in 2024.

•Adjusted gross margin1 for 2025 was 32.3%, compared to 34.6% in 2024.

•Net loss for 2025 was $196.4 million, compared to net income of $13.4 million in 2024. Included in this year’s loss were non-cash impairments of $30.6 million in intangible assets, $58.2 million in goodwill, and a $5 million equity investment.

•Adjusted EBITDA1 loss was $28.6 million for 2025, compared to adjusted EBITDA of $60.3 million in 2024.

•Medical Transportation Services revenue for 2025 was $200.8 million, compared to $193.5 million in 2024.

•Mobile Health Services revenue for 2025 was $121.4 million, compared to $423.1 million in 2024. This decline was entirely due to the wind-down of migrant-related programs.

Select Corporate Highlights for the Fourth Quarter of 2025 and Recent Weeks

•Combined revenues from the Company’s “healthcare at any address” business – which includes our care gap closure, transitions of care, remote patient monitoring, mobile phlebotomy and virtual care services – tripled to $12.8 million in Q4 2025, compared to $4.3 million in Q4 2024.

•Company achieved record volumes across all major business lines, with US medical transportation increasing 11%, healthcare in the home increasing 113%, mobile phlebotomy increasing 16%, remote patient monitoring increasing 16%, and virtual care & lab orders increasing 50% when comparing fourth quarter 2025 to fourth quarter 2024.

•DocGo’s SteadyMD announced an immediate expansion of its clinical workforce to meet rising virtual care demand for branded GLP-1 weight loss care, and achieved their highest monthly revenue on record in February 2026.

•Surpassed 1.45 m